RCRC
Saudi Arabia’s King Salman Bin Abdul Aziz Al Saud has appointed Fahd Abdulmohsan Al-Rasheed as President of the Royal Commission for Riyadh City (RCRC), following his appointment in 2018 as Advisor at the Royal Court.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200120005223/en/
Al-Rasheed’s career has featured various leadership roles in key Saudi public and private sector organizations. From January 2008 to September 2018, he served as Chief Executive Officer and Board member of Emaar the Economic City, the publicly listed developer of the King Abdullah Economic City (KAEC).
KAEC is not only the first publicly listed greenfield city in the world, but is also considered one of the largest private sector led projects globally. Located on the Red Sea coast of Saudi Arabia and covering 181 square kilometers, it contains advanced urban and environmental sustainability features. During his tenure at KAEC, Al-Rasheed spearheaded the development of King Abdullah Port, the first private port in the region and one of the world’s 100 largest port facilities. Over 120 local and international companies established a corporate or industrial base in KAEC, making it a leading regional center for logistic and industrial services. Concurrently, Al-Rasheed led the development of multiple residential, utility and recreational projects to make the Economic City an attractive, integrated tourism and residential destination.
Previously, Al-Rasheed served as CFO & Deputy Governor at the Saudi Arabian General Investment Authority (SAGIA) and worked at Saudi Aramco, where he led several corporate finance initiatives.
In addition to his new position as RCRC President, Fahd Al-Rasheed will continue his roles as:
- Vice Chairman of the Board of Trustees of the Prince Mohammed bin Salman College of Business and Entrepreneurship – the first of its kind in the Kingdom – which aims to be an incubator and trainer of business entrepreneurs and future leaders across key sectors (governmental, private sector and civil community foundations). MiSK Foundation, Babson International College and Lockheed Martin Corporation are amongst the college’s founders;
- Founder and Chairman of the non-profit Red Sea Foundation, based in Geneva, which promotes trade across the Red Sea region;
- Board Member of the New Cities Foundation (a non-profit foundation based in Geneva);
- Board Member of Emaar Economic City; King Abdullah Port; and the Diplomatic Quarters Authority in Riyadh.
Al-Rasheed was honored as a Young Global Leader by the World Economic Forum in 2011.
He holds a bachelor’s degree in Business Administration from Washington University in St. Louis, USA, and an MBA from Stanford Business School. He graduated from the Advanced Management Program in Real Estate Development at the Harvard Graduate School of Design.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
